2,4,6-Trimethoxyamphetamine
2,4,6-Trimethoxyamphetamine, also known as TMA-6 or ψ-TMA-2, is a psychedelic drug of the phenethylamine, amphetamine, and Ψ-PEA families. It is one of the positional isomers of trimethoxyamphetamine.
Use and effects
In his 1991 book PiHKAL, Alexander Shulgin gave a dose range for TMA-6 of 25 to 50mg and a duration of 12 to 16hours. Threshold effects occur at 20mg, a full hallucinogenic state occurs at 30 to 40mg, and erratic results have been reported for 40 to 80mg. The drug is said to have about 8 to 10times the potency of mescaline.The effects of TMA-6 have been reported to include ease with concepts and writing, body tingling, walking unsteadiness, thinking difficulty or intoxication, difficulty with tasks, funniness, hilarity, and laughter, difficulty sleeping, inner chill, visual sparkle, stomach queasiness, diarrhea, reduced appetite, fluctuating emotions, personal insights, visuals, colors, and feelings of "energy flow". Additional reported effects include enjoyable lightheadedness, euphoria, perceptual distortion, synesthesia, and nausea.
Pharmacology
Pharmacodynamics
TMA-6 shows affinity for serotonin receptors in rat stomach fundus strips as well as in rat brain membranes. In a later study, it showed no affinity for the serotonin 5-HT1A or dopamine D2 receptors. Subsequently, it was reported to be a potent serotonin 5-HT2A receptor full agonist, with an of 29.2nM and an of 107%. The drug was inactive as a monoamine reuptake inhibitor and releasing agent in rat brain synaptosomes. The drug is a potent monoamine oxidase A inhibitor, with an of 400nM. This is in contrast to TMA and TMA-2, which are inactive in this regard.TMA-6 fully substitutes for the psychedelic drugs DOM and 5-MeO-DMT in rodent drug discrimination tests. It also partially substitutes for dextroamphetamine in rodent drug discrimination tests.